Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 344 results for "Tecfidera"

Surveyed European Neurologists Expect to Prescribe Biogen Idec...

/PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will ... BusinessWeek, 4 days ago

38 images for Tecfidera

ABC News 4 Charleston, 4 days ago
Daily Record, 1 week ago
Triangle Business Journal, 1 week ago
Review Seeker, 1 month ago, 3 weeks ago
ABC News 4 Charleston, 1 month ago
Pharma Letter, 1 month ago
Pharma Times, 1 month ago
Pharma Times, 2 months ago
Pharma Times, 2 months ago
Jutia Group

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting

- Two-Year Data from Pivotal Phase 3 ADVANCE Study for PLEGRIDY (Peginterferon Beta-1a) to Be Presented - - New TECFIDERA (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients ...
 BusinessWeek6 days ago Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting  Benzinga.com6 days ago BIOGEN IDEC : to Report Clinical Data from Its Neurology Portfolio at AAN Annual Meeting  4 Traders3 days ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting  Jutia Group5 days ago
Review Seeker

Biogen Idec's Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral..

/PRNewswire/ --Decision Resources Group finds that Biogen Idec's Tecfidera, the third-to-market oral disease-modifying therapy (DMT), has become the patient share leader among the oral options available for the treatment of relapsing forms of ...
 ADVFN India1 month ago Biogen Idec''s Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch  Asian Hospital & Healthcare Management1 month ago

This Oral MS Drug Is Off to a Quick Start

Biogen Idec 's ( NASDAQ: BIIB ) Tecfidera wasn't the first oral multiple sclerosis drug, but is sure has gotten off to a much faster start than Novartis ' ( NYSE: NVS ) Gilenya, which was approved by the FDA in 2010 and Sanofi 's ( NYSE: ...
 Motley Fool1 month ago

Biogen receives Health Canada approval for treatment of multiple sclerosis

The Health Canada approval of TECFIDERA in April 2013 was based on findings from two global Phase III two-year studies, DEFINE and CONFIRM. In DEFINE, TECFIDERA, administered twice-daily, significantly reduced the proportion of patients who relapsed ...
 Individual.com1 month ago Health Canada Approves New Strength For TECFIDERA(TM), A First-Line Oral Treatment For Multiple Sclerosis  Canada NewsWire2 months ago

Better Buy: Biogen Or Amgen?

At Biogen, Tecfidera continues its blistering pace forward in winning U.S. multiple sclerosis market share from Novartis (NYSE: NVS As a result, shares in both Biogen and Amgen are hitting new highs, but is one a better buy than the other? ...
 Motley Fool1 month ago Better Buy: Biogen Or Amgen?  Daily Finance1 month ago

Biogen Buys Rights to Experimental Alzheimer's Drugs

Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan's Eisai Co.'s experimental Alzheimer's disease medicines as it seeks to add treatments for brain disorders. Biogen will pay Eisai an ...
 Pharmaceutical Manufacturing Magazine1 month ago Biogen Acquires Rights to Eisai's Alzheimer's Drugs  Bloomberg1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 0, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Dimethyl fumarate (Tecfidera) approved in Scotland

07 April 2014 Author: The Scottish Medicines Consortium (SMC) has approved dimethyl fumarate (Tecfidera, formerly BG-12) as a treatment for people with relapsing remitting MS in Scotland. Daily Record SMC Dimethyl fumarate (Tecfidera) ...
 Multiple Sclerosis Trust1 week ago Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland  Multiple Sclerosis Trust1 week ago Biogen's MS drug needs to woo NICE  Pharma Field1 month ago ViewPoints: NICE rejection of Biogen Idec's Tecfidera illustrates disconnect between US, European MS markets  FirstWord Pharma1 month ago

Here's Why You Should Look Beyond NICE's Pushback on Tecfidera

It shouldn't surprise anyone that the U.K.'s top cost watchdog, the National Institute for Health and Care Excellence, otherwise known as NICE, has balked at Biogen's (NASDAQ: BIIB After all, this isn't new territory for MS patients in the United ...
 Motley Fool1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less